Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) reached a new 52-week high during trading on Thursday . Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. Further ReadingReceive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.